GlassScriptPhysician profile
Stephen A Szabo
NPI 1689698771
$79,765.62
in general payments reported to CMS, 2019-2025
36 companies · $631 in 2025
The $631 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74K · 2020: $592 · 2021: $628 · 2022: $1,632 · 2023: $1,834 · 2024: $285 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,712 · Travel and Lodging: $1,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,711.62 |
| Travel and Lodging | $1,038.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $73,960.60 | 2019-2020 | |
| Axonics, INC. | $2,856.68 | 2021-2024 | Axonics, Bulkamid |
| Abbvie INC. | $492.64 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Novo Nordisk INC | $456.65 | 2020-2023 | Wegovy |
| Boston Scientific Corporation | $296.33 | 2025 | Axonics |
| Aspira Women'S Health INC | $211.52 | 2021-2022 | |
| Astellas Pharma US INC | $204.83 | 2023-2025 | Veozah, Myrbetriq |
| Caldera Medical, INC | $137.42 | 2025 | |
| Organon LLC | $132.58 | 2021-2025 | Nexplanon |
| Laborie Medical Technologies Corp. | $122.56 | 2019 | |
| Pfizer INC. | $88.04 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $83.77 | 2023-2024 | Gemtesa, Myfembree |
| Daiichi Sankyo INC. | $76.51 | 2019-2023 | Injectafer |
| Coopersurgical, INC. | $59.46 | 2021-2023 | Summit Doppler |
| Baxter Healthcare | $55.27 | 2022-2025 | Perclot |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $48.51 | 2019 | |
| Covidien LP | $43.36 | 2020 | |
| Exeltis, USA INC. | $39.79 | 2020-2023 | Slynd |
| Ethicon US, LLC | $33.53 | 2022-2023 | Surgicel Nu-Knit, Harmonic, Enseal |
| Hologic Sales and Service, LLC | $32.92 | 2019-2024 | Thinprep 2000 Processor, Aptima |
| Valencia Technologies Corporation | $32.07 | 2025 | Ecoin Device Kit |
| Mayne Pharma Commercial LLC | $31.89 | 2023 | |
| Avion Pharmaceuticals | $29.52 | 2020-2022 | |
| Therapeuticsmd, INC. | $29.50 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $25.93 | 2019 | |
| Smith+Nephew, INC. | $24.56 | 2019-2020 | |
| Agile Therapeutics, INC. | $19.38 | 2021 | |
| Medtronic, INC. | $18.45 | 2022 | |
| Exact Sciences Corporation | $18.32 | 2025 | The Cologuard Plus Collection Kit |
| Davol INC. | $17.51 | 2024 | Arista Ah Flexitip |
| Coloplast Corp | $16.06 | 2019 | |
| Shield Therapeutics INC | $15.31 | 2023 | Accrufer |
| Amgen INC. | $15.15 | 2019 | |
| Urovant Sciences INC | $15.15 | 2021 | |
| Lupin INC. | $13.07 | 2020 | |
| Meditrina | $10.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Szabo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.